Zydus reveals positive data from EVIDENCES IV phase 2 clinical trial
Category: #health  By Mateen Dalal  Date: 2019-10-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zydus reveals positive data from EVIDENCES IV phase 2 clinical trial

Non-alcoholic Steatohepatitis (NASH) is a progressive disease which can ultimately lead to cirrhosis and liver failure. Liver transplantation is the only treatment for managing advanced cirrhosis with liver failure. There are currently no U.S. Food and Drug Administration (USFDA) approved treatments for NASH cirrhosis. Thus, researchers are coming up new with treatments that can treat this disease effectively.

Zydus Cadila is a global pharmaceutical company that has reportedly announced encouraging results from the EVIDENCES IV clinical trial of Saroglitazar Magnesium, an investigational molecule in U.S., undergoing clinical evaluation for treatment of liver diseases like NAFLD (Non-alcoholic fatty liver disease) with PCOS (polycystic ovary syndrome), Primary Biliary Cholangitis (PBC) and Nonalcoholic Steatohepatitis (NASH).

According to reports, Saroglitazar Magnesium achieved the primary endpoint in the EVIDENCES IV clinical trial, a double-blind, placebo-controlled, and randomized study that registered 106 patients with NAFLD comprising NASH across 20 U.S. based clinical sites.

Reportedly, for 16 Weeks; patients were randomly assigned in a ratio of 1:1:1:1 to receive the dose of 1mg, 2mg or 4mg or a matching placebo once in a day before breakfast in the morning.

Speaking on the trial, Prof. Naga P. Chalasani, MD and Associate Dean for Clinical Research and Director, Division of Gastroenterology & Hepatology, Indiana University School of Medicine, said that an authority in the areas of NAFLD and drug-induced liver injury was the lead Principal Investigator of the EVIDENCES IV trial.

Chalasani claims that 4mg dose of Saroglitazar had considerably improved liver biochemistries, insulin resistance, hepatic steatosis, dyslipidemia with zero weight gain or fluid retention. He added that these results were quite promising as there is a dire need for a drug that improves not only liver disease treatment but also is important co-morbidities such as dyslipidemia and insulin resistance.

Reliable sources cite that the study achieved primary endpoint in the EVIDENCES IV clinical trial when there was a percentage change in serum ALT levels at week 16, from baseline, in the Saroglitazar Magnesium groups comparing to the placebo group.

Source Credit - https://zyduscadila.com/public/pdf/pressrelease/Zydus_NASH_US_Press_Release.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...